Inhalation Sciences signs IRS contract worth 29 700 EUR with returning established pharma client

Report this content

(Stockholm 5 May, 2021) Inhalation Research Services (IRS), ISAB’s contract research organization, has signed a new order worth 29.7 KEUR. The order includes key preclinical feasibility evaluations, to be carried out on PreciseInhale®, and an advanced dissolution and absorption study on DissolvIt®, ISAB’s leading in vitro tool which delivers exceptionally precise, predictive and life-like data, significantly reducing the risk of clinical failure in later trials.

The total value of the order is 29 700 EUR. The contract includes key feasibility and evaluation studies on substances to be carried out on ISAB’s flagship aerosol generator PreciseInhale®, and an advanced dissolution and absorption study carried out on DissolvIt®. Fully commercialized in 2020, the ability of DissolvIt® to deliver highly predictive, life-like data closely resembling clinical outcomes, makes it recognized by many as unique and leading in its field. DissolvIt® is specifically developed for drugs administered via the lungs, in contrast to many other dissolution methods that are developed from techniques originally designed for solid drugs intended for gastrointestinal uptake.

ISAB CEO Manoush Masarrat “When clients of this calibre return to run tests of this importance, it shows how valuable the data we deliver are, and how appreciated our IRS work is. PreciseInhale® and DissolvIt® deliver premium, high-precision ‘go / no – go data’ that can effectively de-risk your research, meaning you get it right from the start and potentially save huge costs further down the line. We’re delighted to be working with this valuable client again.”

For more information about Inhalation Sciences, please contact:

Manoush Masarrat, CEO


Mobile: +46 (0)73 628 9153

About Inhalations Sciences Sweden AB (publ)

Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments and services for research into inhalation. The company’s patented lab instruments PreciseInhale® and DissolvIt® enable researchers in the pharma industry  to make drug pipeline decisions at an early stage, saving time and resources for R&D departments, and enables researchers in academic institutions to define how aerosols and small particles impact our lungs, and so our health, when being inhaled.  

The information above was provided by Inhalation Sciences Sweden AB according to EU Market Abuse Regulations. The information was provided, through the above contact person, for publication on May 5, 2021 at 08.30.